Short-Course Palliative Radiotherapy in Non–Small-Cell Lung Cancer
- 1 February 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 23 (1) , 89-93
- https://doi.org/10.1097/00000421-200002000-00024
Abstract
From February 1993 to October 1997, 91 consecutive patients with inoperable (stage IIIB-IV) histologically confirmed non-small-cell lung cancer underwent palliative hypofractionated radiotherapy. Recently, the Medical Research Council studies on hypofractionated short-course radiotherapy (8.5 Gy x 2) have reported high control of symptoms caused by thoracic disease without toxicity. Based on these experiences and our previous positive trial on short-course radiotherapy (8 Gy x 2) in metastatic spinal cord compression, a prospective study of short-course palliative radiotherapy in non-small-cell lung cancer was carried out. The regimen was 16 Gy given in two 8-Gy fractions, 1 week apart. Eighty-one patients were evaluable for response to treatment. Forty-eight (59%) patients were 65 years or older. Forty (49%) patients were naive to radiotherapy, whereas 41 (51%) had previous cisplatin-based chemotherapy. All but four stage IV patients (95%) had poor Eastern Cooperative Oncology Group performance status (i.e., 2-3). Clinical palliation was achieved in 62 (77%) patients. Performance status improved in 59 (73%) patients. The median palliation time ranged from 28% to 57% of patient survival. The median survival from the beginning of treatment was 148 days (range, 5-681 days). No difference in overall survival according to stage and previous chemotherapy was observed. Only performance status conditioned survival (performance status 1-2 vs. performance status 3; p = 0.0289). Short-course radiotherapy gave good results in terms of clinical palliation for thoracic symptoms, even in patients with poor performance status and pretreated with chemotherapy. The median palliation time was approximately 50% of patient survival time. Treatment was generally well tolerated-only 4 (5%) patients experienced World Health Organization grade III dysphagia. No late toxicity was recorded. The two-fraction regimen had social and economic advantages compared with the conventional ones.Keywords
This publication has 12 references indexed in Scilit:
- Short-course radiotherapy (8 Gy × 2) in metastatic spinal cord compression: An effective and feasible treatmentInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group.Thorax, 1993
- A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance statusBritish Journal of Cancer, 1992
- Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractionsBritish Journal of Cancer, 1991
- Once-a-week vs conventional daily radiation treatment for lung cancer: Final reportInternational Journal of Radiation Oncology*Biology*Physics, 1988
- An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchusClinical Radiology, 1988
- Treatment of non-small-cell lung cancer.Journal of Clinical Oncology, 1986
- Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1986
- Palliative radiotherapy for inoperable carcinoma of the lung: Final report of a rtog multi-institutional trialInternational Journal of Radiation Oncology*Biology*Physics, 1985
- COMPARISON OF TREATMENT POLICIES IN INOPERABLE BRONCHIAL CARCINOMAThe Lancet, 1971